Loading…
← CockpitCompetitor Analysis › DOCS.L Dr. Martens PlcOpen in the cockpit ↗

Dr. Martens PlcDOCS.LCompetitor analysis, valuation and peers

United Kingdom · GBP·Consumer Discretionary›Apparel/Footwear
Momentum laggard 13
Mkt cap
$824M
US dollars, full cap
Free float
58%
of shares outstanding
$/day
$881,975
20-day average traded
Fwd P/E
13.0×
forward earnings
ROIC−WACC
+2.5 pp
WACC 7.6%
Hurdle
-4 pp
Req g minus delivered
Next earnings
20 days
26 Nov 2026
Close · GBP£64.00
1D-0.5%
1W-2.4%
1M-5.6%
3M-23.6%
6M+2.9%
YTD-16.4%
1Y-26.3%
ATR %5.2%
52w lowhigh29.2% off high

What Dr. Martens does

Employees: 2,377

Dr. Martens at a glance

Size Dr. Martens (DOCS.L) is a United Kingdom Consumer Discretionary company (Apparel/Footwear) with a market value of $824M, the 239th largest of 363 United Kingdom companies the cockpit tracks. Shares closed at £64.00 on 6 Nov 2026.

Performance Over six months the shares gained 2.9%, against -0.3% for the median peer and +3.6% for the United Kingdom market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 2.9% over the last twelve months (peer median +7.0%); the operating margin is 10.1% (peer median 7.8%).

Valuation It trades at 13.0× forward earnings against a peer median of 21.1× (5th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.5 points above its cost of capital (7.6% WACC).

Next results Next results expected around 26 Nov 2026 (exchange calendar; dates can move).

Relative performance

10012014011 May 202611 Aug 20266 Nov 2026DOCS.L 105Peer median 99
Six months, rebased to 100: Dr. Martens against the median of its 20 peers (local-currency closes).

Dr. Martens financials

Reported figures in GBP; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue£765M£766M£788M£877M£1.00B
Revenue growth—-3%-10%-12%—
Gross profit£437M£439M£439M£503M£564M
EBITDA£146M£142M£133M£199M£245M
Net income£23.8M£23.8M£4.50M£69.2M£129M
Free cash flow£116M£116M£160M£133M£32.1M
Capital expenditure£11.9M£11.9M£18.7M£28.4M£51.4M
Total debtn/a£391M£402M£469M£446M

Quarterly statements and history in the cockpit →

Dr. Martens competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-20%0%+20%603877GOOSBATAINDIA002029RELAXOLOGI-B783900215460319636126015663009818016603511603587603608600400CAMPUS603001456ADOCS.L6-month return →1-month return →
Up and to the right = strong over both horizons. Dr. Martens is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%50×100×603877GOOSBATAINDIA002029RELAXOLOGI-B78390021546031963612601566600400CAMPUS456ADOCS.LRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dr. Martens is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%603877GOOSBATAINDIA002029RELAXOLOGI-B783900215460319636126015663009818016603511603608600400CAMPUS603001DOCS.LGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dr. Martens is the large dot.

Dr. Martens competitors and peer comparison

How Dr. Martens compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dr. Martens against its 20 peers (data as of 6 Nov 2026)
MeasureDOCS.LPeer medianRank in peer set
1-month return-5.6%-4.1%10th lowest of 21
6-month return+2.9%-0.3%11th highest of 21
Distance from 52-week high-29.2%-32.1%10th highest of 21
Revenue growth (TTM)-2.9%+7.0%2nd lowest of 21
Operating margin10.1%7.8%8th highest of 21
Forward P/E13.0×21.1×5th cheapest of 17
Growth the price implies (Req g, 7 yrs)-3.7%5.0%7th least demanding of 21
Growth delivered (Del g)-0.2%+2.1%10th lowest of 20
Hurdle (Req g minus delivered)-3.5 pp-5.1 pp10th most demanding of 20
ROIC minus cost of capital+2.5 pp+0.7 pp9th highest of 21
EV / EBITDA5.7×12.7×cheapest of 10
Net debt / EBITDA1.4×0.4×5th most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Dr. Martens DOCS.LUnited Kingdom$824M+3%-3%10%13.0×-3.7%-0.2%
Ningbo Peacebird Fashion 603877.SSChina$839M-15%-2%4%26.6×-13.1%-7.5%
Canada Goose GOOS.TOCanada$850M-23%+12%10%13.3×5.5%+11.0%
Bata India BATAINDIA.NSIndia$868M-12%+5%9%39.2×28.9%+15.5%
Fujian Septwolves Industry 002029.SZChina$873M-20%+1%-3%20.2×4.5%-2.0%
Relaxo Footwears RELAXO.NSIndia$768M-4%+2%8%32.5×33.5%+2.8%
Logistea LOGI-B.STSweden$759M+6%+18%83%12.9×14.2%+40.4%
Shoei Co. Ltd. (7839) 7839.TJapan$750M+29%+2%28%17.0×-8.1%+10.7%
Bxn 002154.SZChina$740M-19%+6%7%11.2×-10.3%+6.5%
Shanghai Puyuan Chemical Materials 603196.SSChina$964M-46%+78%12%19.9×16.2%-0.2%
World 3612.TJapan$701M-5%+15%6%8.4×-5.1%+9.5%
JOEONE 601566.SSChina$975M+4%+1%6%52.6×-2.9%+2.1%
Zhonghong Pulin Medical Products 300981.SZChina$990M+5%+11%9%n/a-1.7%-13.1%
Onward 8016.TJapan$659M+4%+7%5%9.2×1.0%+6.1%
AIMER 603511.SSChina$657M-28%-2%4%n/a-7.2%-1.6%
Dazzle Fashion 603587.SSChina$1.03B+10%+7%16%22.1×-9.2%-3.5%
Topscore Fashion 603608.SSChina$1.05B+28%+9%4%n/a51.6%-9.4%
Jiangsu Hongdou Industrial 600400.SSChina$1.06B+11%+22%-9%102.3×13.7%-1.3%
Campus Activewear CAMPUS.NSIndia$640M-21%+14%11%30.3×32.8%+20.1%
ZheJiang AoKang Shoes 603001.SSChina$619M+19%-31%-8%n/a23.6%-6.8%
Human Made 456A.TJapan$1.10B+39%+27%30%45.5×7.7%n/a

Questions

Which companies are Dr. Martens's closest peers?
The cockpit's peer set: Ningbo Peacebird Fashion (603877.SS), Canada Goose (GOOS.TO), Bata India (BATAINDIA.NS), Fujian Septwolves Industry (002029.SZ), Relaxo Footwears (RELAXO.NS), Logistea (LOGI-B.ST), Shoei Co. Ltd. (7839) (7839.T), Bxn (002154.SZ).
Is Dr. Martens expensive compared with its peers?
On forward p/e it trades at 13.0× against a peer median of 21.1×, 5th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Dr. Martens stock performed?
Over six months to 6 Nov 2026 the shares returned +2.9% against -0.3% for the median peer; over one year -26.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.